VivoSeq
Oncology

Advanced Renal Cell Carcinoma (arcc)

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Advanced Renal Cell Carcinoma (aRCC) is an early-stage landscape with 4 programs across 2 companies. The most active players are Regeneron, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Fianlimab

Regeneron

Ipilimumab

Bristol-Myers Squibb

Nivolumab

Bristol-Myers Squibb

Cemiplimab

Regeneron

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Recruiting·—·Phase 2·NCT07188896·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)